Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrology (asn) kidney week 2023

“the totality of data from the protect study demonstrates filspari is effective, safe and has an important place in the igan treatment landscape

TVTX Ratings Summary

TVTX Quant Ranking